

Edgar Filing: VIREXX MEDICAL CORP - Form 6-K

VIREXX MEDICAL CORP  
Form 6-K  
December 12, 2005

FORM 6-K

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

For the month ended

December 2005

Commission File  
Number  
1-32608

VIREXX MEDICAL CORP.  
(Translation of registrant's name  
into English)

8223 Roper Road NW, Edmonton,  
Alberta, Canada T6E 6S4  
(Address of principal executive  
offices)

Indicate by check mark whether the registrant files or will file  
annual reports under cover Form 20-F or Form 40-F.

Form 20-F        Form 40-F    .....

Indicate by check mark if the registrant is submitting the Form 6-  
K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-  
K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether by furnishing the information  
contained in this Form, the registrant is also thereby furnishing  
the information to the Commission pursuant to Rule 12g3-2(b)  
under the Securities Exchange Act of 1934.

Yes ..... No ..X..

If "Yes" is marked, indicate below the file number assigned to  
the registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_\_

EXHIBIT LIST

| Exhibit           | Description  |
|-------------------|--|
| 99.1 News Release | (ViRexx Files Clinical Trial Application For<br>Hepatitis B Therapeutic Vaccine) |

Edgar Filing: VIREXX MEDICAL CORP - Form 6-K

99.2 News Release (ViRexx Announces Founder Dr. Antoine  
Noujaim Honoured With Centennial Medal)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of  
1934, the registrant has duly caused this report to be signed on  
its behalf by the undersigned, thereunto duly authorized.

VIREXX MEDICAL CORP.

Date: December 8, 2005

By: /s/ Marc Canton

Marc Canton, President